latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/dascena-s-algorithm-to-detect-kidney-failure-gets-us-fda-breakthrough-device-tag-59344506 content esgSubNav
In This List

Dascena's algorithm to detect kidney failure gets US FDA breakthrough-device tag

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Dascena's algorithm to detect kidney failure gets US FDA breakthrough-device tag

U.S. Food and Drug Administration granted breakthrough-device designation to Dascena Inc's algorithm that helps predict acute kidney injury in patients before clinical diagnosis.

Acute kidney injury is an abrupt loss of kidney function due to sudden damage. It occurs as a complication to other serious illnesses, and the impact can range from the return of organ function after a while to complete kidney failure.

Dascena's Previse is a cloud-based machine learning algorithm that is designed to detect acute kidney injury at an earlier stage. The program has shown higher sensitivity and predictive value compared to a doctor's assessment based on clinical criteria, according to a July 7 news release.

The designation will allow for expedited approval of the device, as it may provide more effective treatment of life-threatening or irreversibly debilitating diseases.

Oakland, Calif.-based Dascena is a private healthcare technology company that develops algorithm software for diagnostics and biomarkers.